The clinical variability of neurocysticercosis is due to a series of factors such as number, location, form, dimensions and stage of development of the parasite, the nature of its action on the organism and the individual immunological response of the hosu. 4, 6 . Thus, diagnosis is very difficult, especially in not highly endemic areas or in regions were laboratory support is lacking. Another important feature to be considered in the approach to neurocysticercosis is the lack of an alternative program of antiparasitic treatment. The high coast of treatment with praziquantel and the side effects' of corticosteroids 5 are factors that have led to the search for new treatment programs.
Albendazole, a drug belonging to the benzimidazole group, is characterized by high therapeutic indices as a polyvalent antihelmintic agent 1 * and with efficacy in patients with hydatic cysts 7 . Dextrochloropheniramine is a potent anti-histaminic with good penetration in the central nervous system which acts on cerebral histamine receptors by a competitive mechanism 2 .
The objective of the present research was to evaluate for the first time the therapeutic action of albendazole in combination with dextrochloropheniramine in patients with cysticercosis.
Fourty Group III: 15 to 30 mg/kg/day, in two series of 21 and 30 days. All of the patients in the three groups also received uninterruptedly 18 mg/day dextrochloropheniramine administered orally, during and 4 to 6 months after the end of treatment.
All patients were evaluated by clinical examination and laboratory tests, during and immediatelly after, as well as 5 to 20 months after the end of treatment. All potentially fertile women were submitted to pregnancy tests before and during treatment with albendazole. The ethical norms of Helsinki 
